Cytokinetics Inc

1 Sept 2026, 20:09 UTC

Cytokinetics Inc shares are higher as Truist and H.C. Wainwright reaffirm Buy ratings, citing positive momentum and potential from recent ESC conference insights.

31 Aug 2026, 23:01 UTC

Cytokinetics Inc shares are lower in after-market trading amid broader market declines. Concerns over potential interest rate hikes may be influencing the downward trend.

28 Aug 2026, 22:01 UTC

Cytokinetics Inc shares are higher after announcing positive Phase 3 trial results for aficamten at the European Society of Cardiology Congress.

26 Aug 2026, 20:08 UTC

Cytokinetics shares advance amid social media discussions of a $100 price target, reflecting gains since Tuesday's close despite mixed U.S. market performance.

14 Aug 2026, 19:26 UTC

Cytokinetics shares are higher as H.C. Wainwright maintains a Buy rating and Barclays raises its price target to $110 amid strong sales momentum.

13 Aug 2026, 23:21 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from three consecutive lower sessions, though still below the 20-day moving average.

12 Aug 2026, 19:46 UTC

Cytokinetics Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

11 Aug 2026, 19:11 UTC

Cytokinetics Inc shares declined as CEO Robert I. Blum sold 7,500 shares at $76.76, raising investor concerns about executive confidence in the company.

10 Aug 2026, 19:46 UTC

Cytokinetics shares rise as Truist upgrades rating and raises price target to $112, while Citizens increases its target to $110 following strong Q2 results.

8 Aug 2026, 00:01 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from earlier declines. The stock remains below its 20-day moving average.

7 Aug 2026, 22:51 UTC

Cytokinetics shares are rising in after-market trading, recovering from earlier session lows amid positive sentiment in US equities and mixed labor data.

6 Aug 2026, 23:21 UTC

Cytokinetics reports Q2 2026 net loss of $198.8 million, better than expected. Shares are higher in after-market trading amid positive sentiment.

5 Aug 2026, 20:06 UTC

Cytokinetics Inc shares are higher amid positive market sentiment and easing crude oil prices, despite a shift from recent daily closing trends.

4 Aug 2026, 23:01 UTC

Cytokinetics Inc is higher in after-market trading, gaining since Tuesday's close, though still below its 20-day moving average with no specific news identified.

3 Aug 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 Jul 2026, 20:02 UTC

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 Jul 2026, 18:46 UTC

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 Jul 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28 Jul 2026, 19:06 UTC

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27 Jul 2026, 19:56 UTC

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24 Jul 2026, 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22 Jul 2026, 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21 Jul 2026, 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20 Jul 2026, 19:22 UTC

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.